Dr. Shore on extended follow-up data for darolutamide in nonmetastatic CRPC

Video

Neal D. Shore, MD, medical director of the Carolina Urologic Research Center, discusses extended follow-up data from the phase 3 ARAMIS trial of darolutamide (Nubeqa) in nonmetastatic castration-resistant prostate cancer that were shared during the 2021 ASCO Annual Meeting. The FDA approved the androgen receptor pathway inhibitor in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.

Related Videos
Dr. Jasmeet Kaur in an interview with Urology Times
Dr. Martin Voss in an interview with Urology Times
Dr. Jacqueline Brown in an interview with Urology Times
blurred clinic hallway
Dr. Dalia Kaakour in an interview with red Urology Times backdrop
Dr. Maria Teresa Bourlon in an interview with Urology Times
Dr. David Braun in an interview with Urology Times
Dr. Neeraj Agarwal in an interview with Urology Times
Dr. Saby George in an interview with Urology Times
Dr. Laura Bukavina in an interview with Urology Times
Related Content
© 2024 MJH Life Sciences

All rights reserved.